Adinazolam Mesylate | CAS#57938-82-6

MedKoo Cat#: 526341 | Name: Adinazolam mesylate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Adinazolam (brand name: Deracyn) is a benzodiazepine derivative, more specifically, a triazolobenzodiazepine (TBZD). It possesses anxiolytic, anticonvulsant, sedative, and antidepressant properties. Adinazolam was developed by Dr. Jackson B. Hester, who was seeking to enhance the antidepressant properties of alprazolam, which he also developed. Adinazolam was never FDA approved and was never available to the public.

Chemical Structure

Adinazolam mesylate

CAS#57938-82-6 (mesylate)

Theoretical Analysis

MedKoo Cat#: 526341

Name: Adinazolam mesylate

CAS#: 57938-82-6 (mesylate)

Chemical Formula: C20H22ClN5O3

Exact Mass:

Molecular Weight: 447.94

Elemental Analysis: C, 53.63; H, 4.95; Cl, 7.91; N, 15.63; O, 10.72; S, 7.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

57938-82-6 (mesylate) 37115-32-5 (free base)

Synonym

Adinazolam Mesylate; Adinazolamum; Deracyn; U-41,123; U 41,123; U41,123; U-41123; U 41123; U41123;

IUPAC/Chemical Name

1-(8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-1-yl)-N,N-dimethylmethanamine mesylate

InChi Key

FENBITQPWFCMEB-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H18ClN5.CH4O3S/c1-24(2)12-18-23-22-17-11-21-19(13-6-4-3-5-7-13)15-10-14(20)8-9-16(15)25(17)18;1-5(2,3)4/h3-10H,11-12H2,1-2H3;1H3,(H,2,3,4)

SMILES Code

CN(C)CC1=NN=C2N1C3=CC=C(Cl)C=C3C(C4=CC=CC=C4)=NC2.OS(=O)(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Schedule IV controlled substance - Canada

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 447.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Venkatakrishnan K, Culm KE, Ehrenberg BL, Harmatz JS, Corbett KE, Fleishaker JC, Greenblatt DJ. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol. 2005 May;45(5):529-37. PubMed PMID: 15831776. 2: Ajir K, Smith M, Lin KM, Fleishaker JC, Chambers JH, Anderson D, Nuccio I, Zheng Y, Poland RE. The pharmacokinetics and pharmacodynamics of adinazolam: multi-ethnic comparisons. Psychopharmacology (Berl). 1997 Feb;129(3):265-70. PubMed PMID: 9084065. 3: Gao P, Skoug JW, Nixon PR, Ju TR, Stemm NL, Sung KC. Swelling of hydroxypropyl methylcellulose matrix tablets. 2. Mechanistic study of the influence of formulation variables on matrix performance and drug release. J Pharm Sci. 1996 Jul;85(7):732-40. PubMed PMID: 8818998. 4: Gao P, Meury RH. Swelling of hydroxypropyl methylcellulose matrix tablets. 1. Characterization of swelling using a novel optical imaging method. J Pharm Sci. 1996 Jul;85(7):725-31. PubMed PMID: 8818997. 5: Ju RT, Nixon PR, Patel MV, Tong DM. Drug release from hydrophilic matrices. 2. A mathematical model based on the polymer disentanglement concentration and the diffusion layer. J Pharm Sci. 1995 Dec;84(12):1464-77. PubMed PMID: 8748330. 6: Ju RT, Nixon PR, Patel MV. Drug release from hydrophilic matrices. 1. New scaling laws for predicting polymer and drug release based on the polymer disentanglement concentration and the diffusion layer. J Pharm Sci. 1995 Dec;84(12):1455-63. PubMed PMID: 8748329. 7: Gao P, Nixon PR, Skoug JW. Diffusion in HPMC gels. II. Prediction of drug release rates from hydrophilic matrix extended-release dosage forms. Pharm Res. 1995 Jul;12(7):965-71. PubMed PMID: 7494816. 8: Gao P, Fagerness PE. Diffusion in HPMC gels. I. Determination of drug and water diffusivity by pulsed-field-gradient spin-echo NMR. Pharm Res. 1995 Jul;12(7):955-64. PubMed PMID: 7494815. 9: Fleishaker JC, Garzone PD, Chambers JH, Sirocco K, Weingartner H. Comparison of the spectrum of cognitive effects of alprazolam and adinazolam after single doses in healthy subjects. Psychopharmacology (Berl). 1995 Jul;120(2):169-76. PubMed PMID: 7480549. 10: Ogata M, Tahara T, Nishimura T. NMR spectroscopic characterization of adinazolam mesylate: pH-dependent structure change in aqueous solution and active methylene. J Pharm Sci. 1995 Jun;84(6):786-90. PubMed PMID: 7562424. 11: Stemm NL, Skoug JW, Robins RH. Gradient high performance liquid chromatographic assay for degradation products of adinazolam mesylate in a sustained release tablet formulation. Pharm Res. 1995 May;12(5):738-45. PubMed PMID: 7479561. 12: Golden PL, Warner PE, Fleishaker JC, Jewell RC, Millikin S, Lyon J, Brouwer KL. Effects of probenecid on the pharmacokinetics and pharmacodynamics of adinazolam in humans. Clin Pharmacol Ther. 1994 Aug;56(2):133-41. PubMed PMID: 8062489. 13: Chambers JH, Fleishaker JC. The lack of effect of smoking on the pharmacokinetics and pharmacodynamics of adinazolam and N-demethyladinazolam. Biopharm Drug Dispos. 1994 May;15(4):263-72. PubMed PMID: 8068865. 14: Fleishaker JC, Greist JH, Jefferson JW, Sheridan AQ. Relationship between concentrations of adinazolam and its primary metabolite in plasma and therapeutic/untoward effects in the treatment of panic disorder. J Clin Psychopharmacol. 1994 Feb;14(1):28-35. PubMed PMID: 8151001. 15: Fleishaker JC, Sisson TA, Sramek JJ, Conrad J, Veroff AE, Cutler NR. Psychomotor and memory effects of two adinazolam formulations assessed by a computerized neuropsychological test battery. J Clin Pharmacol. 1993 May;33(5):463-9. PubMed PMID: 8331205. 16: Fleishaker JC, Hulst LK, Ekernäs SA, Grahnén A. Pharmacokinetics and pharmacodynamics of adinazolam and N-desmethyladinazolam after oral and intravenous dosing in healthy young and elderly volunteers. J Clin Psychopharmacol. 1992 Dec;12(6):403-14. PubMed PMID: 1474178. 17: Fleishaker JC, Wright CE. Pharmacokinetic and pharmacodynamic comparison of immediate-release and sustained-release adinazolam mesylate tablets after single- and multiple-dose administration. Pharm Res. 1992 Apr;9(4):457-63. PubMed PMID: 1495889. 18: Fleishaker JC, Hulst LK, Smith TC, Friedman H. Clinical pharmacology of adinazolam and N-desmethyladinazolam mesylate following single intravenous infusions of each compound in health volunteers. Eur J Clin Pharmacol. 1992;42(3):287-94. PubMed PMID: 1577047. 19: Skoug JW, Borin MT, Fleishaker JC, Cooper AM. In vitro and in vivo evaluation of whole and half tablets of sustained-release adinazolam mesylate. Pharm Res. 1991 Dec;8(12):1482-8. PubMed PMID: 1808610. 20: Kroboth PD, Maxwell RA, Fleishaker JC, Van Thiel DH, Smith RB. Comparison of adinazolam pharmacokinetics and effects in healthy and cirrhotic subjects. J Clin Pharmacol. 1991 Jun;31(6):580-6. PubMed PMID: 1880225.

View History

BMS-98633

MedKoo CAT#: 466288

CAS#: unknown